TLR3 and prostate cancer: These data were in-line with previous reports that TLR3 ligands can induce apoptosis of human prostate cancer cells via dephosphorylation of AKT [34], and that Sorafenib can impair cell proliferation by inhibiting the MEK/ERK pathway [35].